Spontaneous regression of neoplasms: New possibilities for immunotherapy

Expert Opinion on Biological Therapy

Volumn 2, Issue 5, 2002, Pages 459-476

  Bodey, Bela ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Angiogenesis; Antineoplastic immunotherapy; Carcinogenesis; Cellular immunophenotype; Dedifferentiation; Growth factors; Hormonal spontaneous regression; IL 2; mAb; Metastasis; Neoplastic cell redifferentiation; Neoplastic cell transformation

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7; MONOCLONAL ANTIBODY; TELOMERASE; TUMOR NECROSIS FACTOR; TUMOR VACCINE; HORMONE;

CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL DIVISION; CELL IMMORTALIZATION; CELLULAR IMMUNITY; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; HUMAN; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE; REVIEW; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL TRANSFORMATION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANIMAL; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; HORMONES; HUMAN; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; NEOPLASM REGRESSION, SPONTANEOUS; NEOPLASMS; ONCOGENES; T-LYMPHOCYTES, CYTOTOXIC; ANIMALS; HUMANS;

MAMMALIA;

EID: 0035987389     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.5.459     Document Type: Review

References (228)

1. Tumor suppressor genes
2. Immunophenotypically varied cell subpopulations in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy
3. Immunocytochemical detection of p53 protein overexpression in primary human osteosarcomas
4. The DCC gene product in cellular differentiation and colorectal tumorigenesis
5. P53 and mdm-2: Interactions between tumor suppressor gene and oncogene products
6. Molecular markers in cancer diagnosis
7. Molecular genetic tumor markers in the early diagnosis and screening of non-small-cell lung cancer
8. Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis
9. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in astrocytic gliomas and their correlation to cell proliferation
10. Genetic instability of cancer: Why a metastatic tumor is unstable and a benign tumor is stable
11. Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies
12. Clinical and prognostic significance of Ki-67 and proliferating cell nuclear antigen expression in childhood primitive neuroectodermal brain tumors
13. Nm23/ nucleoside diphosphate (NDP) kinase expression in human malignant melanomas. Significance and implications in tumor biology
14. Genetic alterations during colorectal-tumor development
15. Phenobarbital promotes multistage pulmonary carcinogenesis in MNU-inoculated L-W rats
16. Growth mechanism and cancer progression
17. Some tumor cell protein kinases activated by receptors as markers, including elastin receptors
18. Spontaneous regression of cancer
19. Regression of cancer after intensive meditation
20. Regression of osteogenic sarcoma metastases associated with intensive meditation
21. Some peculiarities in the behavior of certain malignant and innocent growths
22. Fluctuations in the growth rate of malignant tumors in man, with special reference to spontaneous regression
23. The transformation of a malignant paravertebral sympathicoblastoma into a benign ganglioneuroma
24. The apparent disappearance of pulmonary metastasis in a case of hypernephroma following nephrectomy
25. The spontaneous regression of cancer. A review of cases from 1900 to 1987
26. The medical aspects of carcinoma of the breast, with a note on the spontaneous disappearance of secondary growths
27. Spontaneous regression of hypernephroma
28. Spontaneous regression of cancer. The metabolic triumph of the host?
29. Spontaneous regression of cancer
30. A biological approach to an understanding of regression
31. Biological viewpoints of neoplastic regression
32. Regression of neoplasms in invertebrates with special emphasis on mollusca
33. Tumor reversal and tumor suppression in plants
34. Immune defense in arthropods - How chelicerates, crustaceans, insects and myriapods protect themselves against disease
35. Spontaneous remission of breast cancer
36. Spontaneous regression of carcinoma of the stomach
37. Spontaneous regression of a germinoma in the pineal body after placement of a ventriculoperitoneal shunt
38. Spontaneous regression of hepatocellular carcinoma
39. Spontaneous regression of a large hepatocellular carcinoma with portal vein tumor thrombi: Report of a case
40. Spontaneous involution of pilocytic astrocytoma in a patient without neurofibromatosis type 1: Case report
41. Regression of gastric T cell lymphoma with eradication of Helicobacter pylori
42. Regression of a gastric lymphoma of mucosa-associated lymphoid tissue after eradication of Helicobacter pylori in a kidney graft recipient
43. Spontaneous regression of congenital leukaemia with an 8;16 translocation
44. Spontaneous regression of a primary cerebral tumour following postoperative middle cerebral artery territory infarction
45. Spontaneous regression of stage IV clear cell carcinoma of the endometrium in a patient with essential thrombocytosis
46. Spontaneous regression of melanoma may offer insight into cancer immunology
47. The heterocytotoxicity of human serum. III. Studies of the serum levels and distribution of activity in human populations
48. Spontaneous tumor regression: Possible relationships to in vitro parameters of tumor immunity
49. The cytotoxic action of normal human serum on certain cells propagated in vitro
50. Spontaneous regression of neuroblastoma: An experimental approach
51. Complement-dependent lysis of Ehrlich ascites cells by human serum (ascitolysin) is lowered in cancer patients and raised in pregnant women
52. Natural cytotoxicity of human serum. A natural IgM 'antibody' sensitizes transformed murine cells to the lyric action of complement
53. Spontaneous remission of neuroblastoma
54. Monoclonal antibodies to a glycolipid antigen of human neuroblastoma cells
55. Eradication of neuroblastoma cells in vitro by monoclonal antibodies and complement: Method for purging autologous bone marrow
56. How frequent is spontaneous remission of neuroblastomas? Implications for screening
57. Molecular basis of clinical heterogeneity in neuroblastoma
58. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma
59. Biologic control of cancer
60. Cancers complicating organ transplantation
61. An immunologic approach to the treatment of cancer?
62. Efforts to explain spontaneous regression of cancer
63. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2
64. Oncogenes and growth factors
65. Fighting cancer with designer cells
66. Cellular therapy
67. Passive immunotherapy of cancer in animals and man
68. Adoptive immunotherapy of cancer: Accomplishments and prospects
69. Lymphokine activated killing as treatment for human cancer: Clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes
70. Autologous tumour-specific cytotoxic T cell clone established from tumour infiltrating lymphocytes (TIL) of malignant ascites in the absence of recombinant interleukin 2 (rIL-2): Activation by autologous tumour cell alone
71. Immunophenotypic characterization of infiltrating poly- and mononuclear cells in childhood brain tumors
72. Immunophenotypic characterization of human primary and metastatic melanoma infiltrating autologous immunological effector cells
73. Interleukin-2 antitumor and effector cell response
74. Multiple sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles
75. Purification of three cytotoxic lymphocyte granule serine proteases that induce apoptosis through distinct substrate and target cell interactions
76. The Fas death factor
77. Natural killer cells as the effector which mediates in vivo apoptosis in AK-5 tumor cells
78. Biology of natural killer cells
79. Apoptosis: Molecular mechanism in programmed cell death
80. Suppressor cell activity in melanoma-draining lymph nodes
81. Thin regressing malignant melanoma: Significance of concurrent regional lymph node metastases
82. Molecular mechanisms used by tumors to escape immune recognition: Immunogenetherapy and the cell biology of major histocompatibility complex class I
83. Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells
84. Epstein-Barr virus positive Burkitt's lymphoma cells not recognized by virus specific T-cell surveillance
85. Immunotherapy of a murine tumor with interleukin-2: Increased sensitivity after MHC class I gene transfection
86. Role of the major histocompatibility complex class I antigens in tumor growth and metastasis
87. Nonsecretory apoptotic killing by human NK cells
88. Antitumor functions of natural killer cells and control of metastases
89. Interleukin-2 promotes the motility of dendritic cells and their accumulation in lung and skin
90. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network
91. Lymphoreticular infiltration in human tumours: Prognostic and biological implications: A review
92. The stromal reaction of tumors: An expression of immune surveillance
93. Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma
94. Spontaneous regression of metastatic malignant melanoma
95. Natural cell-mediated immunity
96. The clonal evolution of tumor cell populations
97. Tumor cell instability, diversification and progression to the metastatic phenotype: From oncogene to oncofetal expression
98. Oncogene involvement in tumor regression: H-ras activation in the rabbit keratoacanthoma model
99. Transforming growth factor beta and cell cycle regulation
100. The approaching era of the tumor suppressor genes
101. Ras genes
102. The ras gene family and human carcinogenesis
103. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas
104. Spontaneous remission of metastatic lung cancer following myxedema coma - An apoptosis-related phenomenon?
105. Expression of transforming growth factor-beta type II receptors in the cells of the human thymic microenvironment during ontogenesis
106. Differential manipulation of normal and chronic myeloid leukemia stem cell proliferation in vitro
107. Spontaneous regression of malignant melanoma: A review of the literature on incidence, clinical features, and possible mechanisms
108. Spontaneous remission in acute leukemia: Report of a case complicated with eclampsia
109. Acute myelogenous leukemia in pregnancy
110. Cancer of the breast and menopause
111. Spontaneous regression of breast cancer
112. Spontaneous regression of breast carcinoma: Follow-up report and literature review
113. Modulation of leukaemia blast colony growth by steroid hormones
114. Oestrogen receptors in human malignant melanoma
115. High dose tamoxifen in malignant melanoma
116. Role of hormones and growth factors in melanomas
117. Possible role of retinoic acid binding protein in retinoid stimulation of embryonal carcinoma cell differentiation
118. Relationship between binding affinities to cellular retinoic acid-binding protein and in vivo and in vitro properties for 18 retinoids
119. Induction of differentiation of embryonal carcinoma cells by retinol: Possible mechanisms
120. Murine embryonal carcinoma cells differentiate in vitro in response to retinol
121. Structure-activity relationships of a new series of retinoidal benzoic acid derivatives as measured by induction of differentiation of murine F9 teratocarcinoma cells and human HL-60 promyelocytic leukemia cells
122. Induction of differentiation of embryonal carcinoma cells by retinoids
123. New benzoic acid derivatives with retinoid activity: Lack of direct correlation between biological activity and binding to cellular retinoic acid binding protein
124. Identification of a receptor for the morphogen retinoic acid
125. Teratocarcinoma: Model for a developmental concept of cancer
126. Teratocarcinomas and mammalian embryogenesis
127. Models and concepts derived from human teratogenesis and oncogenesis in early life
128. Regulation and patterns of endogenous and exogenous gene expression during differentiation of embryonal carcinoma cells
129. The induction of differentiation in teratocarcinoma stem cells by retinoic acid
130. Hormonal induction of differentiation in teratocarcinoma stem cells: Generation of parietal endoderm by retinoic acid and dibutyryl cAMP
131. Epithelial layer formation in differentiating aggregates of F9 embryonal carcinoma cells
132. Evidence for the existence of an early common biochemical pathway in the differentiation of F9 cells into visceral or parietal endoderm: Modulation by cyclic AMP
133. The evolution of mature teratoma from malignant testicular tumors
134. Morphological differentiation of human choriocarcinoma cells induced by methotrexate
135. Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment
136. All trans retinoic acid as differentiation therapy for acute promyelocytic leukemia. I. Clinical results
137. The genetic and biologic aspects of treatment response and resistance in male germ cell cancer
138. Spontaneous regression of cancer: New insights
139. Solid stress inhibits the growth of multicellular tumor spheroids
140. Biomechanical aspects of growth and tissue engineering
141. Fibrosis in immune control of mammary-tumor growth
142. Unusual growth characteristics of human melanoma xenografts in the nude mouse: A model for desmoplasia, dormancy and progression
143. The invasive growth of malignant tumours: An experimental interpretation based on elastic-jelly models
144. The invasive growth of malignant turnouts as a purely mechanical process
145. Patterns of vasculature in two pairs of related fibrosarcomas in the rat and their relation to tumour responses to single large doses of radiation
146. The vascular pattern of the spontaneous C3H mouse mammary carcinoma and its significance in radiation response and in hyperthermia
147. The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma
148. Determinants of tumor blood flow: A review
149. Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites
150. Cell and environment interactions in tumor microregions: The multicell spheroid model
151. Cancer biotherapy with interferon, interleukin-2 and tumor-derived activated cells (TDAC)
152. Human gene marker/therapy clinical protocols
153. Immune responses to tumour antigens: Implications for antigen specific immunotherapy of cancer
154. Estrogen-progestin replacement therapy and endometrial cancer
155. Complete regression of hepatocellular adenoma after withdrawal of oral contraceptives
156. Phenotypic characteristics of tumour-infiltrating-lymphocytes in human oesophageal cancer tissues defined by quantitative two colour analysis with flow-cytometry
157. Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy
158. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma
159. Isolation and expansion of lymphocytes from gastrointestinal tumour tissue
160. Interleukin-2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: Isolation, characterization, and antitumor activity
161. Prevention of lymph node metastases by adoptive transfer of CD4+ T lymphocytes admixed with irradiated tumor cells
162. The development of new immunotherapies for the treatment of cancer using interleukin-2
163. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12
164. Progress in human tumour immunology and immunotherapy
165. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma
166. Melanoma-reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types
167. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase
168. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase
169. Tumor infiltrating lymphocytes from non-renal urological malignancies
170. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors
171. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer
172. Large-scale expansion in interleukin-2 of tumor infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy
173. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: A pilot trial
174. Growth of tumor derived activated T-cells for the treatment of cancer
175. Immunoselection of a human melanoma Resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures
176. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity
177. T-cell based cancer immunotherapy: Direct or redirected tumor-cell recognition?
178. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma
179. 2 bispecific antibodies
180. Use of anti-CD3 and anti-CD16 bispecific monoclonal antibodies for the targeting of T and NK cells against tumor cells
181. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16
182. Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Thl differentiation and recruitment of MHC-independent cytotoxicity
183. Bifunctional antibody retargeting in vivo-activated T lymphocytes: Simplifying clinical application
184. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody
185. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: Increased efficacy with multiple injections and CD28-induced costimulation
186. Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies
187. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody
188. The role of apoptosis in bispecific antibody-mediated T-cell cytotoxicity
189. A mouse/human- chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes
190. Biologic properties of a bispecific single-chain antibody directed against 17-IA (EpCAM) and CD3: Tumor cell-dependent T cell stimulation and cytotoxic activity
191. Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells
192. Strategies for gene therapy
193. The genetic modification of T cells for cancer therapy: An overview of laboratory and clinical trials
194. Interleukin-4 promotes the growth of tumor infiltrating lymphocytes cytotoxic for human autologous melanoma
195. MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens
196. Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: Monitoring the humoral immune response
197. Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines
198. IL-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response
199. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4
200. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma
201. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin 12, or GM-CSF
202. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells
203. Gene-modified tumor cells as cellular vaccine
204. Immunological memory induced by genetically transduced tumor cells
205. IL-12 stimulation but not B7 expression increases melanoma killing by patient cytotoxic T lymphocytes (CTL)
206. Irradiated B-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML
207. Allogeneic murine melanoma cell vaccine: A model for the development of human allogeneic cancer vaccine
208. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity
209. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: Role of immune cell subpopulations
210. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells
211. Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: Implications for autologous vaccine production
212. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4
213. +-mediated rejection of established tumors
214. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor
215. Generation of effective cancer vaccines genetically engineered to secrete cytokines using adenovirus-enhanced transferrinfection (AVET)
216. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
217. New developments in the virus therapy of cancer: A historical review
218. Human gene transfer: Characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man
219. In vivo antitumor effect of cytotoxic T lymphocytes engineered to produce interferon-gamma by adenovirus-mediated genetic transduction
220. Ex vivo manipulation of cell subsets for cell therapies
221. Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor alpha for the treatment of malignant gliomas
222. A spacer region between the single chain antibody-and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity